7 / 9
Page 20
allied
academies
Journal of Current Pediatric Research | Volume: 22
Joint Event
August 16-17, 2018 | Paris, France
Primary Healthcare
12
th
International Conference on
International Conference and Medicare Expo on
&
Pediatrics Health Care
E
xtremely preterm infants are at high risk of morbidity and
death. In the United States in 2016, approximately twenty-
eight percent of all extremely preterm infants died within the
first year of life. Among infants born at 22, 23, and 24 weeks
gestation, survival to one year of age was 6%, 27%, and 60%,
respectively and increased further for each 1-week increase
in gestational age, from 78% at 25 weeks to 94% at 28 weeks.
Major neonatal morbidities are common for survivors of
preterm births including: sepsis, periventricular leukomalacia,
intraventricular hemorrhage, bronchopulmonary dysplasia,
necrotizing enterocolitis, retinopathy of prematurity, chronic
lung disease, cerebral palsy, severe visual impairment and
hearing impairment. Although survival rates for extremely
low birth weight premature infants have improved, rates of
neonatal morbidity remain high.
Opioid use in pregnancy has escalated dramatically in recent
years, echoing the epidemic observed in the general population
in the United States. As a result, a significant increase in the
numberofbabiesbornwithneonatalabstinencesyndrome(NAS)
has also been observed. NAS is a constellation of neurologic,
gastrointestinal, and musculoskeletal disturbances in the
newborn associated with opioid withdrawal from intrauterine
exposure to an opioid. These infants require specialized care
that typically results in longer and high cost hospital stays.
Non-pharmacologic interventions are the recommended initial
treatment for NAS. However, pharmacologic treatment such as
morphine continues to be a mainstay in the management of
NAS.
This presentationwill provide the results fromanon-going study
of the developmental outcomes of extremely premature infants
actively participating in a Neonatal Developmental Follow-Up
Clinic and on a new Family–Centered Neonatal Abstinence
Syndrome Treatment Model.
Speaker Biography
Eileen R McGrath in an assistant professor of pediatrics and public health; co-
director and training director of the University of Arizona Leadership Education in
Neurodevelopmental and Related Disabilities Training Program and director of the
NeonatalDevelopmentalFollow-upClinicattheUniversityofArizona inTucson,Arizona,
USA. She has extensive experience teaching university students in early childhood
special education, training early intervention practitioners, and teaching premature
infants and children with low incidence neurodevelopmental disabilities. She has
conductedresearchontheeffectsofsystemschangeonthefield(earlychildhoodspecial
education), service recipients, providers, and on the effects of implementing family-
centered services on families, early intervention service coordinators, practitioners
and the service delivery systems. Her current research focuses on the predictors
of developmental outcomes of high-risk and developmentally delayed infants;
the impact of prematurity on a diagnosis of autism or other neurodevelopmental
disorder; and on a Family-Centered Neonatal Abstinence Syndrome Treatment Model.
e:
ermcgra@peds.arizona.eduEileen R McGrath
The University of Arizona College of Medicine, USA
Neurodevelopmental outcomes of extremely low and very low birth weight premature
infants and family-centered Neonatal Abstinence Syndrome treatment models
Notes:
Eileen R McGrath
, Pediatrics & Primary HealthCare 2018, Volume 22
DOI: 10.4066/0971-9032-C1-001